Perspectives of people with HIV (PWH) 12 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)

AUTHORS

W. Valenti¹, D. Dandachi², D. Cunningham³, R. Hsu⁴, K. Nguyen⁵, P. Teichner⁵, A. Jean-Louis⁶, M. Reynolds⁶, D. Richardson⁶, C. Garris⁵


INSTITUTIONS

¹Trillium Health/University of Rochester, Rochester, United States, ²University of Missouri-Columbia, Division of Infectious Diseases, Department of Medicine, Columbia, United States, ³Pueblo Family Physicians, Phoenix, United States, ⁴AHF & NYU Langone Health, New York, United States, ⁵ViiV Healthcare, Durham, United States, ⁶RTI Health Solutions, Research Triangle Park, United States